About AnchorDx
AnchorDx is a company based in Guangzhou (China) founded in 2015. AnchorDx has raised $73 million across 3 funding rounds from investors including Orbimed, Arch Venture Partners and Frontline BioVentures. AnchorDx operates in a competitive market with competitors including Strand Life Sciences, Invitae, Genome Medical, Myriad Genetics and Fulgent Genetics, among others.
- Headquarter Guangzhou, China
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$73 M (USD)
in 3 rounds
-
Latest Funding Round
$40 M (USD), Series C
Feb 22, 2021
-
Investors
Orbimed
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of AnchorDx
AnchorDx has successfully raised a total of $73M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $40 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AnchorDx
AnchorDx has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Arch Venture Partners and Frontline BioVentures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked |
Investor details for AnchorDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AnchorDx
Investment portfolio details for AnchorDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AnchorDx
Detailed financials for AnchorDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Anchordx Comparisons
Peer comparison for AnchorDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AnchorDx
AnchorDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Strand Life Sciences, Invitae, Genome Medical, Myriad Genetics and Fulgent Genetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Home-based genetic tests for detecting diseases are provided to individuals.
|
|
| Locked | Locked | Locked |
Genomic testing services are provided clinically and directly to consumers.
|
|
| Locked | Locked | Locked |
Molecular diagnostics and personalized medicine for cancer are developed.
|
|
| Locked | Locked | Locked |
Provider of genetic testing services for carrier screening cardiovascular diseases, epilepsy and cancer
|
Detailed competitors of AnchorDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Anchordx
Complete news archive for AnchorDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AnchorDx
AnchorDx was founded in 2015.
AnchorDx is headquartered in Guangzhou, China. It is registered at Guangzhou, Guangdong, China.
AnchorDx is a funded company, having raised a total of $73M across 3 funding rounds to date.
AnchorDx was founded in 2015 in Guangzhou, China, within the biotechnology sector focused on genomics. A high-throughput gene sequencing platform is developed for clinical applications, supporting early detection of genetic diseases. Proprietary tests are offered, including non-invasive prenatal testing, pre-implantation carrier screening, cancer diagnostics, and liquid biopsy analyses. Operations emphasize intervention to lower disease incidence through accessible sequencing technologies.
AnchorDx's top competitors include Strand Life Sciences, Fulgent Genetics and Centogene.
AnchorDx has 6 investors. Key investors include Orbimed, Arch Venture Partners, Frontline BioVentures, WuXi PharmaTech, and Marathon Venture Partners.